Basking Biosciences Doses First Patients in Phase 2 Clinical Trial of Reversible Thrombolytic BB-031 for Acute Ischemic Stroke
Novel RNA aptamer designed to inhibit the function of von Willebrand Factor and promote thrombolysis Columbus, Ohio – Sept. 10, 2024 – Basking Biosciences (Basking), a clinical-stage biopharmaceutical company developing a novel acute thrombolytic therapy, today announced that the first patients have been dosed in RAISE, a Phase 2 clinical trial evaluating BB-031 in patients […]
